M&A / Deals

Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers

BioPharma Dive

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.

M&A / Deals Immunology & Inflammation Read full story

pharminent April 15, 2026 (Last updated: April 16, 2026)

BioPharma Dive

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.

M&A / Deals Immunology & Inflammation Read full story

Related Stories

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

CordenPharma inks AmbioPharm buyout to continue peptide production expansion

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise